Publication | Closed Access

Three-arm randomised controlled phase 2 study comparing pemetrexed and erlotinib to either pemetrexed or erlotinib alone as second-line treatment for never-smokers with non-squamous non-small cell lung cancer

Second-line TreatmentMedicinePharmacologyClinical TrialsPharmacotherapyControlled Phase 2Cancer TreatmentOncologySmoking Related Lung DiseaseLung Cancer